ProCE Banner Activity

PEARL: Palbociclib + Endocrine Therapy vs Capecitabine in Postmenopausal Women With HR+/HER- MBC and Previous AI Therapy

Slideset Download
Conference Coverage
No significant differences in PFS benefit between palbociclib plus endocrine therapy and single-agent capecitabine, including in women with visceral disease, ESR1 wildtype tumors, and luminal breast cancer, but combination better tolerated.

Released: December 20, 2019

Expiration: December 18, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen